Residual immune dysfunction under antiretroviral therapy

CW Cai, I Sereti - Seminars in immunology, 2021 - Elsevier
CW Cai, I Sereti
Seminars in immunology, 2021Elsevier
The usage of combination antiretroviral therapy in people with HIV (PWH) has incited
profound improvement in morbidity and mortality. Yet, PWH may not experience full
restoration of immune function which can manifest with non-AIDS comorbidities that
frequently associate with residual inflammation and can imperil quality of life or longevity. In
this review, we discuss the pathogenesis underlying chronic inflammation and residual
immune dysfunction in PWH, as well as potential therapeutic interventions to ameliorate …
Abstract
The usage of combination antiretroviral therapy in people with HIV (PWH) has incited profound improvement in morbidity and mortality. Yet, PWH may not experience full restoration of immune function which can manifest with non-AIDS comorbidities that frequently associate with residual inflammation and can imperil quality of life or longevity. In this review, we discuss the pathogenesis underlying chronic inflammation and residual immune dysfunction in PWH, as well as potential therapeutic interventions to ameliorate them and prevent incidence or progression of non-AIDS comorbidities. Current evidence advocates that early diagnosis and prompt initiation of therapy at high CD4 counts may represent the best available approach for an improved immune recovery in PWH.
Elsevier